Metformin Stada

Metformin, the active ingredient in Metformin Stada, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control.

GNH USA supplies Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Stada is indicated for conditions related to abnormal glucose metabolism.

Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. Gestational diabetes mellitus: helps maintain maternal blood glucose within target ranges. Impaired glucose tolerance: delays progression to overt diabetes when used as part of lifestyle management.

Metformin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: watery stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Vitamin B12 deficiency: may develop with long‑term use. - Hypoglycemia: uncommon, usually when combined with other glucose‑lowering agents. - Acute pancreatitis: very rare inflammatory condition of the pancreas.

Metformin requires careful assessment before and during therapy.

Renal function assessment: ensure adequate glomerular filtration before initiation. Hepatic function monitoring: avoid use in severe liver disease. Blood glucose monitoring: adjust dose based on glycemic response. Elderly patients: start at lower dose and titrate cautiously. Congestive heart failure: evaluate risk of lactic acidosis. Store at ambient temperature: keep in original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure. - Cimetidine: increases metformin plasma concentrations. - Alcohol: raises risk of lactic acidosis. - Carbamazepine: reduces metformin effectiveness. - Rifampin: decreases metformin exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors: monitor renal function. - NSAIDs: may impair renal function. - Digoxin: watch for altered plasma levels.